Skip to main content

Advertisement

Table 2 Recent studies concerning SLR

From: Salvage thoracic surgery in patients with lung cancer: potential indications and benefits

Authors Years N Indication Timing of surgery in weeks (range) Mortality (%) Morbidity (%) Follow-up (months) Overall survival (months) Relapse-free survival (months)
Uramoto et al. [12] 2014 8 Mixed n.g 0 25 14 n.g. 5.9
Yang et al. [7] 2015 31 Recurrent or persistent tumor after radiotherapy 18 (8–111) 0l 48 n.g. 32 10
Dickhoff et al. [14] 2016 15 Local recurrence and persistent tumor after chemo-, radiotherapy 21 (3–95) 6.7 40 12.1 46 43.6
Schreiner et al. [3] 2016 9 Local recurrence after chemo-, radiotherapy 30 (12–165) 11 22 30 23 21
Verstegen et al. [17] 2016 9 Recurrent or persistent tumor after stereotactic radiotherapy n.g. 0 33 19 26 n.g.
Shimada et al. [15] 2016 18 Local recurrence and persistent tumor after chemo-, radiotherapy 38 (3–282) 0 28 47 n.g. n.g.
Mizobuchi et al. [18] 2016 12 Recurrent or persistent tumor after radiotherapy 96 (36–312) 0 n.s. 18 n.g. n.g.
Sawada et al. [16] 2017 8 Local recurrence and persistent tumor after chemo-, radiotherapy n.g. 0 38 48 n.g. n.g
This study 2017 30 Mixed n.g. 3 70 15 15 11
 Only GI patients   22 Recurrent or persistent tumor after definitive chemo-, radiotherapy, or previous surgery and ajduvant treatment 24 0 64 22 22 16
  1. n.g.: not given